International Journal of Hematology

, Volume 78, Issue 3, pp 248–250 | Cite as

L-Asparaginase-Based Induction Therapy for Advanced Extranodal NK/T-Cell Lymphoma

  • Kosuke ObamaEmail author
  • Mitsutoshi Tara
  • Kiyoshige Niina
Case Report


We describe treatment of a patient with advanced extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous lesions and hemophagocytic syndrome. Considering the projected poor outcome of conventional treatments, we designed an L-asparaginase-based induction therapy. L-asparaginase (4000 units/day, day 1 to day 7) combined with vincristine (1 mg, day 1) and prednisolone (100 mg/day, day 1 to day 5) was administered by intravenous infusion every 3 weeks. Within a week after treatment was started, excellent response was observed. Because of an allergic reaction to L-asparaginase, 6 courses of CHOP (adriamycin, cyclophosphamide, vincristine and prednisolone) therapy were administered as consolidation after 4 courses of L-asparaginase. The lymphoma was controlled with complete remission lasting longer than 2 years without additional treatment. These results and related reports may contribute to greater therapeutic efficacy against at least some cases of extranodal NK/T-cell lymphoma and other related diseases. Further evaluations based on clinical study are expected to clarify these results.Int J Hematol. 2003;78:248-250.

Key words

NK/T-cell lymphoma L-Asparaginase Epstein-Barr virus 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas: definitions, differential diagnosis, and epidemiology.Am J Surg Pathol. 1996;20:103–111.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Nakamura S, Katoh E, Koshikawa T, et al. Clinicopathologic study of nasal T/NK-cell lymphoma among the Japanese.Pathol Int. 1997;47:38–53.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Takahashi N, Miura I, Chubachi A, Miura AB, Nakamura S. A clinicopathological study of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma.Int J Hematol. 2001;74:303–308.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm.Blood. 1997;89:4501–4513.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Oettegen HF, Old ID, Boyes EA, et al. Inhibition of leukemia in man by L-asparaginase.Cancer Res. 1967;27:2619–2626.Google Scholar
  6. 6.
    Clarkson B, Krakoff I, Burchenal J, et al. Clinical results of treatment with E coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors.Cancer. 1970;25:279–305.CrossRefPubMedGoogle Scholar
  7. 7.
    Muss HB, Spell N, Scudiery D, et al. A phase II trial of PEG-L- asparaginase in the treatment of non-Hodgkin’s lymphoma.Invest New Drugs. 1990;8:125–130.CrossRefPubMedGoogle Scholar
  8. 8.
    Obama K, Tara M, Niina K. L-asparaginase induced complete remission in Epstein-Barr virus positive, multidrug resistant, cutaneous T-cell lymphoma.Int J Hematol. 1999;69:260–262.PubMedGoogle Scholar
  9. 9.
    Nagafuji K, Fujisaki T, Arima F, Ohshima K. L-Asparaginase-induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation.Int J Hematol. 2001;74:447–450.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Murase T, Suzuki M, Toyama K. Complete remission obtained by sequential chemotherapy of L-asparaginase and continuous infusion of bleomycin (ABLE protocol) in a case of refractory diffuse large cell lymphoma of paranasal origin.Rinsho Ketsueki. 1986;27:252–256.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Hutson RG, Kitoh T, Moraga Amander DA, Cosic S, Schuster SM, Kilberg MS. Amino acid control of asparagines synthetase: relation to asparaginase resistance in human leukemia cells.Am J Physiol. 1997;272:C1691-C1699.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer.Nat Genet. 2000;24:236–244.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  • Kosuke Obama
    • 1
    Email author
  • Mitsutoshi Tara
    • 1
  • Kiyoshige Niina
    • 1
  1. 1.Department of Internal MedicineKagoshima City HospitalKagoshimaJapan

Personalised recommendations